Navigation Links
AuraSense Therapeutics Secures Series B Equity Investment
Date:12/22/2011

EVANSTON, Ill., Dec. 22, 2011 /PRNewswire/ -- AuraSense Therapeutics, a biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation- and chemo-therapeutics for a variety of diseases, including applications in oncology, dermatology, neurology, and for cardiovascular disorders, has closed its Series B financing.  Investors included Abbott Biotech Ventures, a subsidiary of Abbott.  Other key individual investors included Patrick Ryan, founder of Aon; David Walt, co-founder of Illumina; Eric Schmidt, Executive Chairman of Google; and Craig Mundie, Chief Research and Strategy Officer of Microsoft.  Terms of the investment were not disclosed.

"We are delighted to complete this financing and have this consortium of investors join us in our mission to transform the field of gene regulation," said Chad Mirkin, co-founder of AuraSense Therapeutics.  "This financing underscores the highly unique benefits of the SNA platform and will accelerate our efforts to develop it to its full potential – supporting therapies for multiple diseases."

Schiff Hardin LLP served as deal counsel to AuraSense Therapeutics for the investment transaction.

About AuraSense Therapeutics, LLC

AuraSense Therapeutics, LLC is a privately held biopharmaceutical company founded by Professors Chad A. Mirkin and C. Shad Thaxton at Northwestern University.  The Company is dedicated to developing and commercializing spherical nucleic acid (SNA™) conjugates.  Its proprietary SNA constructs possess unparalleled biocompatibility and versatility as therapeutics, and they hold great promise for combating the world's most threatening diseases.  The Company's SNA technology overcomes the most difficult obstacles to gene regulation:  genetic targeting with safe and effective in vivo performance.  For additional information about the company, please visit www.aurasensetherapeutics.com.


'/>"/>
SOURCE AuraSense Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DUBLIN , Mar 29, 2017 Research ... Global Market - Forecast to 2023" report to their offering. ... The ablation ... CAGR to reach $20,995.5 million by 2023. Ablation ... wide range of purposes, from cancerous or diseased tissue removal, to ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education Partners’ ... the field must first improve teacher preparation program design. It then asserts that ... that decades of input- and outcome-based research has failed to improve teacher education. ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s ... technology to directly address the resolution to globally reduce the harmful use of ... compound of FDA and TTB approved ingredients that when infused into alcohol, renders ...
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 ... ... call on elected representatives in state legislatures and Congress to protect parental rights ... the public health and safety in America. , The demonstration coincides with a ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of all holidays (IBT World Travel Trends Report). As travelers visit both urban ... range in temperatures, and prolonged sun exposure. In response, the outdoor industry has ...
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
Breaking Medicine News(10 mins):